Silence Therapeutics plc announced its financial results for the third quarter ended September 30, 2026, alongside updates on its business development. The company reported a net loss of $12.4 million for the quarter, or $0.08 per share, compared to a net loss of $21.0 million, or $0.15 per share, in the same period of the prior year. Research and development expenses decreased to $9.3 million from $20.5 million, attributed to the completion of the Phase 3 readiness for zerlasiran in 2025 and reduced personnel costs. General and administrative expenses also declined to $4.9 million from $5.8 million.
As of September 30, 2026, Silence Therapeutics held $247.7 million in cash and cash equivalents, including $201.3 million in gross proceeds from an upsized public offering announced in August. The company’s total outstanding shares were 186,609,073 ordinary shares as of the end of the quarter. In business news, Silence reported positive topline results from its Phase 2 SANRECO trial of divesiran, an investigational siRNA therapy, which supports a best-in-class profile with once-every-three-month dosing. Additionally, on October 19, 2026, Silence entered into a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany. The transaction is expected to close in the first quarter of 2027, subject to regulatory and shareholder approvals.
